Close Menu

Melanoma

News and reporting on melanoma.

The pilot study with the Mayo Clinic is the final step before SkylineDx commences a US trial next year for its molecular test for primary cutaneous melanoma. 

In Cell this week: microinjection of CRISPR-Cas9 enables targeted mutations in Anolis, melanoma proteomic profiling, and more.

The award will fund optimization of the Hemopurifier exosome isolator, with an eye towards developing applications in cancer research and clinical care.

The new project will be the second stage of the QSkin study, which has documented the disease in 44,000 Australians and developed a melanoma risk predictor.

The team analyzed multigene panel test data from Ambry Genetics for 165,000 individuals, focusing on hereditary cancer risk related to 32 genes in six cancer types.

The company reported $10.7 million in total revenues for the quarter and said test report volume for its DecisionDx-Melanoma test grew 27 percent.

The company is developing a test to predict the  risk of a melanoma patient's cancer metastasizing in lymph nodes without the need for biopsy.

Canaccord Genuity began coverage of Castle Biosciences with a Buy rating and a $26 price target, while SVB Leerink assigned an Outperform rating and a $28 price target.

Researchers focused on candidate genes near expression quantitative trait loci identified by combining cancer susceptibility SNPs and available transcriptomic data.

New publications have provided more detailed examples of the platform's research utility and hinted at future clinical applications in immuno-oncology.

Pages

Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.

University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.

NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.

In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.